肝細胞がん治療薬の市場規模、シェア、成長分析、薬剤クラス別、療法タイプ別、治療タイプ別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025年～2032年

肝細胞がん治療薬の世界市場規模は、2023年に14億米ドルと評価され、予測期間（2025年～2032年）にCAGR 8.3％で成長し、2024年の15億2,000万米ドルから2032年には28億7,000万米ドルに成長する見通しです。

世界の肝細胞がん（HCC）治療薬市場は、患者の人口動態の進化、腫瘍学に対する政府支出の増加、標的療法の進歩などを背景に、大きな成長を遂げています。医療技術革新への世界の投資により、新しい治療、特に肝がんに特化した精密医療の導入が加速しています。早期診断の増加は、免疫療法や併用療法の導入の増加とともに、ヘルスケア提供システム全体で肝細胞がん治療薬の利用を拡大しています。バイオマーカー誘導治療や次世代チロシンキナーゼ阻害剤（TKI）など、精密腫瘍学における注目すべき技術革新は、肝細胞がん治療のブレークスルーへの道を開いています。さらに、人工知能を活用した創薬プラットフォームが有望な新規免疫療法の迅速な開発を促進し、市場の将来性をさらに高めています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ

肝細胞がん治療薬市場規模：薬剤クラス別& CAGR（2025年～2032年）

• 市場概要
• PD-1/PD-L1阻害剤
• チロシンキナーゼ阻害剤

肝細胞がん治療薬市場規模：療法タイプ別& CAGR（2025年～2032年）

• 市場概要
• 標的療法
• 免疫療法
• その他

肝細胞がん治療薬市場規模：治療タイプ別& CAGR（2025年～2032年）

• 市場概要
• 薬物療法、手術
• 放射線療法
• 化学療法
• その他

肝細胞がん治療薬市場規模：投与経路別& CAGR（2025年～2032年）

• 市場概要
• 経口
• 注射剤
• その他

肝細胞がん治療薬市場規模：エンドユーザー別& CAGR（2025年～2032年）

• 市場概要
• 病院
• ホームケア
• 専門クリニック
• その他

肝細胞がん治療薬市場規模：流通チャネル別& CAGR（2025年～2032年）

• 市場概要
• 病院薬局
• オンライン薬局
• 小売薬局

肝細胞がん治療薬市場規模：地域別& CAGR（2025年～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Exelixis, Inc.（US）
• Merck & Co., Inc.（US）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（US）
• Eli Lilly and Company（US）
• SillaJen, Inc.（South Korea）
• Bayer AG（Germany）
• Janssen Global Services, LLC（US）
• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Gilead Sciences, Inc.（US）
• GSK plc（UK）
• Takeda Pharmaceutical Company Limited（Japan）
• Amgen Inc.（US）
• Polaris Group（US）
• Hepion Pharmaceuticals, Inc.（US）
• Provectus Biopharmaceuticals, Inc.（US）

結論と提言

Global Hepatocellular Carcinoma Drugs Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.52 billion in 2024 to USD 2.87 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global hepatocellular carcinoma (HCC) drugs market is experiencing significant growth, driven by evolving patient demographics, increased government expenditure on oncology, and advancements in targeted therapies. Worldwide investments in health innovation are accelerating the adoption of new treatments, particularly precision medicine dedicated to liver cancer. The rise of early diagnoses, along with the growing implementation of immunotherapies and combination therapies, is expanding the utilization of HCC medications across healthcare delivery systems. Notable innovations in precision oncology, including biomarker-guided therapies and next-generation tyrosine kinase inhibitors (TKIs), are paving the way for breakthroughs in HCC treatment. Additionally, artificial intelligence-driven drug discovery platforms are facilitating the rapid development of promising new immunotherapies, further enhancing the market's prospects.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatocellular Carcinoma Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatocellular Carcinoma Drugs Market Segments Analysis

Global Hepatocellular Carcinoma Drugs Market is segmented by Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel and region. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors. Based on Therapy Type, the market is segmented into Targeted Therapy, Immunotherapy and Others. Based on Treatment Type, the market is segmented into Medication, Surgery, Radiotherapy, Chemotherapy and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatocellular Carcinoma Drugs Market

The global hepatocellular carcinoma (HCC) drugs market is largely driven by the rising incidence of HCC globally, largely due to chronic hepatitis B and C infections that are becoming resistant to treatment. Additionally, increasing alcohol consumption and the prevalence of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), which are linked to the growing rates of obesity and diabetes, contribute to this upward trend. With a substantial and expanding patient population requiring effective treatment options, there is a consistent demand for both existing therapies and newly developed drugs to address this pressing health challenge.

Restraints in the Global Hepatocellular Carcinoma Drugs Market

The global hepatocellular carcinoma drugs market faces significant obstacles primarily due to the high costs associated with immunotherapies and targeted treatments, which restrict access for patients, particularly in low- and middle-income nations. Additionally, established markets implement stringent health technology assessment (HTA) policies, such as those from NICE and IQWiG, which require lengthy evaluations before providing reimbursement for expensive therapies. This can further limit patient access and delay the introduction of innovative treatments, despite their proven clinical efficacy, thereby hindering the overall growth and development of the market for hepatocellular carcinoma drugs.

Market Trends of the Global Hepatocellular Carcinoma Drugs Market

The Global Hepatocellular Carcinoma (HCC) drug market is witnessing a significant trend towards the rapid expansion of combination therapies, particularly involving PD-1/PD-L1 inhibitors alongside Tyrosine Kinase Inhibitors (TKIs) and anti-angiogenic agents. Notable combinations, such as Roche's Tecentriq (atezolizumab) with Avastin (bevacizumab), have demonstrated remarkable clinical efficacy, including a 42% reduction in mortality risk as observed in the IMbrave150 trial. This trend is further propelled by accelerated approval processes from regulatory bodies like the FDA and EMA, amplifying market growth potential. As clinical outcomes improve, the demand for effective HCC treatments continues to rise, reshaping the landscape of oncological therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Hepatocellular Carcinoma Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• PD-1/PD-L1 Inhibitors
• Tyrosine Kinase Inhibitors

Global Hepatocellular Carcinoma Drugs Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Targeted Therapy
• Immunotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Medication, Surgery
• Radiotherapy
• Chemotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Others

Global Hepatocellular Carcinoma Drugs Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hepatocellular Carcinoma Drugs Market Size & CAGR (2025-2032)

• North America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SillaJen, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Provectus Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations